Results 261 to 270 of about 100,614 (290)

Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs

Drug Resistance Updates, 2023
Baomin Shi
exaly  

Gemcitabine

Reactions Weekly, 2008
openaire   +2 more sources

Gemcitabine

Reactions Weekly, 2004
openaire   +1 more source

Gemcitabine

Reactions Weekly, 2019
openaire   +2 more sources

Gemcitabine

Reactions Weekly, 2014
openaire   +2 more sources

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology, 2007
Steven Gallinger
exaly  

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2008
Giorgio Scagliotti, Johan Filip Vansteenkiste, Digumarti Raghunadha Rao   +2 more
exaly  

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Lancet Oncology, The, 2014
Yi-Long Wu, Shun Lu, Yunchao Huang
exaly  

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Lancet, The, 2016
Katshuhiko Uesaka, Narikazu Boku, Yukiyasu Okamura   +2 more
exaly  

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Lancet, The, 2016
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky   +2 more
exaly